Mason Street Advisors LLC Grows Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Mason Street Advisors LLC lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,272 shares of the medical research company’s stock after purchasing an additional 594 shares during the period. Mason Street Advisors LLC’s holdings in Bio-Rad Laboratories were worth $3,751,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of BIO. Motco purchased a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth approximately $25,000. Berman Capital Advisors LLC purchased a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth approximately $26,000. Valeo Financial Advisors LLC purchased a new stake in shares of Bio-Rad Laboratories during the 3rd quarter worth approximately $40,000. Capital Investment Advisory Services LLC purchased a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth approximately $48,000. Finally, Advisory Services Network LLC increased its stake in shares of Bio-Rad Laboratories by 64.9% during the 2nd quarter. Advisory Services Network LLC now owns 160 shares of the medical research company’s stock worth $50,000 after purchasing an additional 63 shares during the last quarter. 61.76% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP John Hertia sold 838 shares of Bio-Rad Laboratories stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $328.29, for a total transaction of $275,107.02. Following the completion of the sale, the executive vice president now directly owns 18,966 shares of the company’s stock, valued at approximately $6,226,348.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Crowley sold 1,089 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $333.08, for a total transaction of $362,724.12. Following the sale, the executive vice president now directly owns 2,011 shares of the company’s stock, valued at $669,823.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,414 shares of company stock valued at $2,833,735. Insiders own 27.84% of the company’s stock.

Bio-Rad Laboratories stock traded up $2.51 during mid-day trading on Wednesday, reaching $355.23. The company’s stock had a trading volume of 3,144 shares, compared to its average volume of 217,595. The firm’s fifty day moving average price is $340.74 and its two-hundred day moving average price is $320.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.36 and a current ratio of 4.72. Bio-Rad Laboratories, Inc. has a 12-month low of $220.05 and a 12-month high of $358.89. The company has a market capitalization of $10.62 billion, a P/E ratio of 60.83, a PEG ratio of 3.26 and a beta of 1.16.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, October 31st. The medical research company reported $1.61 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.36 by $0.25. Bio-Rad Laboratories had a net margin of 16.14% and a return on equity of 4.30%. The firm had revenue of $560.60 million during the quarter, compared to the consensus estimate of $561.40 million. During the same period last year, the firm earned $0.91 EPS. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. On average, research analysts predict that Bio-Rad Laboratories, Inc. will post 7.2 EPS for the current fiscal year.

Several equities research analysts have recently issued reports on the stock. Barclays raised their price target on shares of Bio-Rad Laboratories from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. They noted that the move was a valuation call. ValuEngine lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. Finally, Goldman Sachs Group upgraded shares of Bio-Rad Laboratories from a “buy” rating to a “conviction-buy” rating and set a $400.00 price objective for the company in a research note on Tuesday, August 20th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $378.75.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Further Reading: 52-Week High/Low

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.